Results 191 to 200 of about 27,341 (230)

Detection and quantification of ezetimibe and its major glucuronide in patients with hepatic impairment via liquid chromatography-tandem mass spectrometry. [PDF]

J Pharm Biomed Anal
Farrera DO, Maloney MM, LaMadrid CS, Lenzen-Hammerel P, Radtke LR, Cherrington NJ.   +5 more
europepmc   +1 more source

Assessing the Cost Effectiveness of an Incremental Lipid-Lowering Therapy Approach After Coronary Artery Bypass Grafting Using Nationwide Data. [PDF]

J Am Heart Assoc
Deo SV, Ciminata G, Mahalwar G, Salerno PRVO, McAllister DA, Elgudin YE, Orkaby A, Virani S, Fremes S, Rajagopalan S, Sattar N, Pell JP.   +11 more
europepmc   +1 more source

Cardiovascular outcomes and adverse drug reactions associated with the use of ezetimibe in combination with a statin in diabetes mellitus patients with higher risk for myocardial infarction: a meta-analysis. [PDF]

BMC Cardiovasc Disord
Zhou Y, Jin J.
europepmc   +1 more source

Computational Prediction of Deleterious SNPs in the GALNS Gene Implicated in Morquio A Syndrome (MPS IVA). [PDF]

ACS Omega
Priya M, Vasudev V, N SK, Ahmed SS, Ramasamy M.   +4 more
europepmc   +1 more source

Statin intensity, prescribing patterns, and LDL‑C reduction following ACS and in CCD patients who underwent PCI in a tertiary care setting. [PDF]

BMC Cardiovasc Disord
Abdelrady S, Zachariah S, Mathew S, Ghannem K.   +3 more
europepmc   +1 more source

Lipid-Lowering Treatment in Familial Hypercholesterolaemia, 1996-2021: A Nationwide Study. [PDF]

Lancet Reg Health Eur
Reeh J, Wulff AB, Nordestgaard BG, Afzal S.   +3 more
europepmc   +1 more source

Global Lipid Guidelines: More Aligned Than They Appear. [PDF]

Glob Heart
Sethi Y, Mahajan K, Banach M.
europepmc   +1 more source